Endo International PLC (NASDAQ: ENDP) recently received a number of ratings updates from brokerages and research firms:

  • 7/31/2017 – Endo International PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/28/2017 – Endo International PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “2017 will continue to be challenging for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Shares of Endo have significantly underperformed the Medical-Drugs industry in the past one year. The company’s Generic segment is also under pressure given the challenging competitive landscape and pricing pressures. With the  company pulling off Opana ER from the market over growing concern of opioid abuse epidemic, the top-line will be further impacted. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. Nevertheless, Endo’s growth-by-acquisition strategy is impressive. Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables.”
  • 7/23/2017 – Endo International PLC had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 7/19/2017 – Endo International PLC was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/16/2017 – Endo International PLC was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “hold” rating on the stock.
  • 7/11/2017 – Endo International PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “2017 will continue to be challenging for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Shares of Endo have significantly underperformed the Medical-Drugs industry in the past one year. The company’s Generic segment is also under pressure given the challenging competitive landscape and pricing pressures. With the  company pulling off Opana ER from the market over growing concern of opioid abuse epidemic, the top-line will be further impacted. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. Concerns relating to pricing are expected to remain a major overhang on the shares. However, Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables.”
  • 7/7/2017 – Endo International PLC had its price target lowered by analysts at Deutsche Bank AG from $18.00 to $15.00. They now have a “buy” rating on the stock.
  • 6/17/2017 – Endo International PLC is now covered by analysts at Guggenheim. They set a “hold” rating and a $12.00 price target on the stock.
  • 6/16/2017 – Endo International PLC is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $12.00 price target on the stock.
  • 6/15/2017 – Endo International PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/14/2017 – Endo International PLC had its “market perform” rating reaffirmed by analysts at William Blair.
  • 6/12/2017 – Endo International PLC was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “hold” rating on the stock.
  • 6/9/2017 – Endo International PLC was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $15.00 price target on the stock, down previously from $22.00.
  • 6/8/2017 – Endo International PLC had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 6/8/2017 – Endo International PLC was given a new $12.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.

Shares of Endo International PLC (NASDAQ ENDP) traded up 0.75% during trading on Monday, reaching $9.45. The company’s stock had a trading volume of 2,621,684 shares. The stock’s 50 day moving average price is $11.45 and its 200 day moving average price is $11.76. Endo International PLC has a 52 week low of $9.21 and a 52 week high of $24.93. The company’s market cap is $2.11 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the prior year, the business posted $1.08 EPS. The business’s revenue was up 7.7% compared to the same quarter last year. Equities research analysts predict that Endo International PLC will post $3.54 EPS for the current year.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.